Cellectis (CLLS) Cash from Operations (2015 - 2026)
Cellectis (CLLS) posted quarterly Cash from Operations of 15410000.0 for Q1 2026, up 10.2% year-over-year from 13983902.7 in Q1 2025, and down 48.75% quarter-over-quarter from 10360000.0 in Q4 2025.
Powered by 
Analysis
Cellectis (CLLS) Cash from Operations (2015 - 2026) Analysis & Trends
Cellectis' Cash from Operations history runs 12 years deep, the most recent figure standing at 15410000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 10.2% year-over-year to 15410000.0; the TTM figure through Mar 2026 stood at 37651000.0 (down 229.19% YoY), while the FY2025 annual figure was 39401000.0, down 271.39% from the prior year.
- Cash from Operations for Q1 2026 stood at 15410000.0, down from 10360000.0 in the prior quarter.
- The five-year high for Cash from Operations was 52180000.0 in Q2 2024, with the low at 36612000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 15410000.0 (2026), against an average of 8471294.12.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations soared 3355.49% in 2023, then slumped 21942.55% in 2025.
- Cellectis' Cash from Operations stood at 1220000.0 in 2022, then jumped by 3355.49% to 39717000.0 in 2023, then sank by 100.12% to 47000.0 in 2024, then plunged by 21942.55% to 10360000.0 in 2025, then plunged by 48.75% to 15410000.0 in 2026.
- Business Quant data shows CLLS's Cash from Operations at 15410000.0 in Q1 2026, 10360000.0 in Q4 2025, and 1571000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -14.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.28 Mn |
| Mar 31, 2026 | -15.41 Mn |
| Dec 31, 2025 | -10.36 Mn |
| Sep 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -10.31 Mn |
| Mar 31, 2025 | -17.16 Mn |
| Dec 31, 2024 | -47,000.00 |
| Sep 30, 2024 | -5.83 Mn |
| Jun 30, 2024 | 52.18 Mn |
| Mar 31, 2024 | -23.32 Mn |
| Dec 31, 2023 | 39.72 Mn |
| Sep 30, 2023 | -17.09 Mn |
| Jun 30, 2023 | -19.04 Mn |
| Mar 31, 2023 | -28.33 Mn |
| Dec 31, 2022 | -1.22 Mn |
| Sep 30, 2022 | -26.04 Mn |
| Jun 30, 2022 | -23.57 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | -21.08 Mn |
| Sep 30, 2021 | -30.43 Mn |